Plasma rich in growth factors promotes dermal fibroblast proliferation, migration and biosynthetic activity.
OBJECTIVE
The use of plasma rich in growth factors (PRGF) has gained importance in many medical fields due to its regenerative potential. The aim of this study is to evaluate the effects of PRGF on primary skin fibroblasts assessing cell proliferation, migration and secretion of growth factors. The age of the patients from who PRGF was prepared was also studied to determine whether it influenced the outcomes.


METHODS
Human dermal fibroblasts were isolated from three healthy volunteers. Using PRGF-Endoret technology, PRGF was prepared from two groups of different ages (18-35 years and 50+ years). The effects of increasing concentration of PRGF (5%, 10% and 20%) on cell proliferation and migration was evaluated. Biosynthetic behaviour of cells was also analysed measuring vascular endothelial growth factor (VEGF), transforming growth factor b1 (TGFb1) and pro-collagen type I secreted levels with or without PRGF treatment.


RESULTS
Mean platelet enrichment reached 2.4X and 2X in 18-35 and 50+ groups respectively. A dose-dependent response was observed in proliferation assays achieving the highest levels with 20% PRGF. Migration was also promoted in cells but not in a dose-dependent manner. Cell proliferation and migration outcomes obtained with PRGF (from both groups) were significantly higher compared to non-stimulated groups (p<0.05), with no statistical significances were observed between the different age groups. Production of VEGF, TGFb and procollagen type I was significantly increased by cells treated with PRGF, however, with the exception of VEGF, no statistical significances were observed between the different age groups.


CONCLUSIONS
Results from this study concluded that PRGF is safe and effective in stimulating skin regeneration by enhancing proliferation, migration and expression of pivotal bioactive molecules involved in wound healing and haemostasis.
Eduardo Anitua Foundation, Vitoria, Spain.|BTI Biotechnology Institute, Vitoria, Spain.
E
E
Anitua
Eduardo Anitua Foundation, Vitoria, Spain.
A
A
Pino
Eduardo Anitua Foundation, Vitoria, Spain.
G
G
Orive
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005347:Fibroblasts / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D053657:Platelet-Rich Plasma; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*; D014945:Wound Healing / Q000502:physiology*; D014947:Wounds and Injuries / Q000188:drug therapy*; D055815:Young Adult
D042461:Vascular Endothelial Growth Factor A
cell proliferation; fibroblast; plasma rich in growth factors; skin regeneration; wound healing